Measuring treatment response in malignant pleural mesothelioma using breathprinting technology
Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates
This study is testing if a special breath-sensing device can help track how well treatment is working for people with malignant pleural mesothelioma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 30 Years to 85 Years |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Locations | 7 sites (Basking Ridge, New Jersey and 6 other locations) |
| Trial ID | NCT06037941 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of electronic nose (E-Nose) technology to assess how patients with malignant pleural mesothelioma respond to standard treatment. Researchers will analyze changes in breathprints over time and compare these changes to standard imaging scans and blood biomarkers. The goal is to determine if E-Nose can provide a non-invasive method to monitor treatment efficacy in these patients.
Who should consider this trial
Good fit: Ideal candidates are adults aged 30-85 who have recently been diagnosed with malignant pleural mesothelioma and have no history of thoracic or extrathoracic cancers.
Not a fit: Patients under 30 or over 85 years old, or those with a history of thoracic or extrathoracic cancer that could lead to pleural metastases, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could offer a new, non-invasive way to monitor treatment responses in patients with malignant pleural mesothelioma.
How similar studies have performed: While the use of breathprinting technology is relatively novel, similar studies have shown promise in other conditions, suggesting potential for success in this application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 30-85 years * No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer) * Recent diagnosis of MPM * Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection Exclusion Criteria: * Aged \<30 or \>85 years at the first outpatient visit * History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases
Where this trial is running
Basking Ridge, New Jersey and 6 other locations
- Memorial Sloan Kettering Basking Ridge (Consent Only) — Basking Ridge, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Monmouth (Consent Only) — Middletown, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Bergen (Consent Only ) — Montvale, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent Only) — Commack, New York, United States (Recruiting)
- Memorial Sloan Kettering Westchester (Consent Only) — Harrison, New York, United States (Recruiting)
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York, United States (Recruiting)
- Memorial Sloan Kettering Nassau (Consent Only) — Uniondale, New York, United States (Recruiting)
Study contacts
- Principal investigator: Gaetano Rocco, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Gaetano Rocco, MD
- Email: roccog@mskcc.org
- Phone: 212-639-3478
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.